Dasatinib in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma

Inclusion Criteria:

• Histologically or cytologically confirmed solid tumor or lymphoma

  • Metastatic or unresectable disease
  • Standard curative or palliative measures do not exist or are no longer effective
  • All solid and lymphoma tumor types are eligible
  • Patients with a liver mass, elevated α-fetoprotein level (i.e., ≥ 500 ng/mL), and positive serology for viral hepatitis consistent with a diagnosis of hepatocellular carcinoma will be eligible without the need for pathologic confirmation of diagnosis
• Measurable or nonmeasurable disease

• Patients with brain metastases requiring corticosteroids must be on a stable or decreasing dose of corticosteroids

  • Prior brain irradiation (whole brain or gamma knife) is required for known brain metastases
  • No untreated (non-irradiated) brain metastases

• No clinically significant pleural effusion, fluid retention, or pericardial effusion

  • Patients with a history of pleurodesis and pleural effusion (malignant or non-malignant) may be eligible but will be treated with caution
  • Patients with a history of ascites are eligible
• Zubrod performance status 0-2
• Life expectancy ≥ 2 months
• Absolute neutrophil count ≥ 1,500/mm³
• Platelets ≥ 100,000/mm³
• Magnesium ≥ lower limit of normal (LLN)
• Potassium ≥ LLN
• Creatinine ≤ 1.5 times upper limit of normal OR creatinine clearance ≥ 60 mL/min
• Patients with abnormal liver function are eligible
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception

• Patients with biliary obstruction for which a shunt has been placed are eligible provided the liver function tests have stabilized

  • Two measurements at least 2 days apart that put the patient in the same hepatic dysfunction stratum will be accepted as evidence of stable hepatic function
  • There must be no evidence of biliary sepsis and at least 2 weeks must have elapsed after the placement of a biliary shunt
• Must be willing to undergo pharmacokinetic sampling
• Must be able to take oral medications

• Patients may not have any clinically significant cardiovascular diseases including the following:

  • Myocardial infarction or ventricular tachyarrhythmia within 6 months
  • Prolonged QTc >= 480 msec (Fridericia correction)
  • Ejection fraction less than normal institutional normal
  • Major conduction abnormality (unless a cardiac pacemaker is present)
  • Patients with any cardiopulmonary symptoms of unknown cause should be evaluated by a baseline echocardiogram with or without stress test as needed in addition to EKG to rule out QTc prolongation; patients with underlying cardiopulmonary dysfunction should be excluded from the study
• No history of allergic reaction to dasatinib or similar compounds
• No ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2, atrial fibrillation of any grade, or QTc interval > 470 msec for females or > 450 msec for males
• No active gastrointestinal bleeding
• No diagnosis of malabsorption syndrome or significant bowel resection affecting absorption
• No clinically significant fluid retention or pericardial effusion

• No uncontrolled serious intercurrent medical illness including, but not limited to, any of the following:

  • Ongoing or serious active infection
  • Symptomatic congestive heart failure
  • Unstable angina pectoris
  • Serious cardiac arrhythmia
  • Uncontrolled diarrhea
  • Psychiatric illness/social situation that would limit compliance with study requirements
• No known HIV-positivity
• Recovered from all prior therapy
• More than 7 days since prior and no concurrent H2-receptor antagonist (e.g., cimetidine, ranitidine, or famotidine)
• More than 7 days since prior and no concurrent proton pump inhibitors (e.g., omeprazole, lansoprazole, esomeprazole, or pantoprazole)
• More than 4 weeks since prior major surgical procedures
• More than 4 weeks since prior and no other concurrent or plans to receive anticancer therapy including chemotherapy, radiotherapy, immunotherapy, or investigational agents
• At least 2 weeks since prior targeted agents with a half-life of < 24 hours
• No prior dasatinib
• Concurrent hormone therapy for prostate carcinoma may be continued
• Concurrent bisphosphonate treatment for bone disease is permitted

• No concurrent therapeutic doses of anticoagulants

  • Low dose warfarin for port prophylaxis is permitted
• No concurrent enzyme-inducing anticonvulsant medications (e.g., phenobarbital, phenytoin, or carbamazepine)
• No concurrent prophylactic colony-stimulating factors